7
Views
1
CrossRef citations to date
0
Altmetric
Review

Immunohistochemistry in gynaecological pathology: a review

Pages 109-119 | Received 02 Jul 2003, Accepted 04 Dec 2003, Published online: 06 Jul 2009

References

  • Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumours. Int J Gynecol Pathol 2000; 20: 64–78.
  • McCluggage WG. Value of inhibin staining in gynecological pathology. Int J Gynecol Pathol 2001; 20: 79–85.
  • McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 2002; 40: 309–26.
  • Pirog EC, Chen Y-T, Isacson C. MIB-1 immunostaining is a beneficial adjunct test for accurate diagnosis of vulvar condyloma accuminatum. Am J Surg Pathol 2000; 24: 1393–9.
  • Brown HM, Wilkinson EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol 2002; 33: 545–8.
  • Wilkinson EJ, Brown HM. Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 2002; 33: 549–54.
  • Pirog EC, Baergen RN, Soslow RA, et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol 2002; 26: 70–5.
  • Kruse A-J, Baak JPA, Helliesen T, et al. Evaluation of MIB-1 positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1501–7.
  • Klaes R, Benner A, Friedrich T, et al. p16 (INK4a) immuno-histochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1387–99.
  • McCluggage WG, Maxwell P. BCL-2 and P21 immunostaining of cervical tuboendometrial metaplasia. Histopathology 2002; 40: 107.
  • Cameron RI, Maxwell P, Jenkins D, et al. Immunohistochemical staining with MIB-1, BCL2, and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histo-pathology 2002; 41: 313–21.
  • Pirog EC, Isacson C, Szaboles MJ, et al. Proliferative activity of benign and neoplastic endocervical epithelium and correlation with HPV DNA detection. Int J Gynecol Pathol 2002; 21: 22–6.
  • Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16 (INK4A), and early endocervical glandular neoplasia. Hum Pathol 2002; 33: 899–904.
  • Negri G, Egarter-Vigl E, Kasal A, et al. p16 (INK4a) is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors. Am J Surg Pathol 2003; 27: 187–93.
  • Franquemont DW, Frierson HF Jr, Mills SE. An immunohistochem-ical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol 1991; 15: 861–70.
  • Devaney K, Tavassoli FA. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumours of the uterus. Mod Pathol 1991; 4: 225–30.
  • Farhood Al, Abrams J. Immunohistochemistry of endometrial stroma sarcoma. Hum Pathol 1991; 22: 224–30.
  • Lillemoe Ti, Perrone T, Norris Hi, et al. Myogenous phenotype of epithelial-like areas in endometrial stromal sarcomas. Arch Pathol Lab Med 1991; 115: 215–19.
  • Staebler A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridiza-tion are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002; 26: 998–1006.
  • Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002; 21: 4–10.
  • McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor aids: the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002; 21: 11–15.
  • Zaino RJ. The fruits of our labours: distinguishing endometrial from endocervical adenocarcinoma. Int J Gynecol Pathol 2002; 21: 1–3.
  • Kamoi S, Alluboury MI, Akin M-R, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int j Gynecol Pathol 2002; 21: 217–23.
  • Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumours of the uterus. Am J Surg Pathol 2002; 26: 403–12.
  • Vang R, Kempson RL. Perivascular epithelioid cell tumour ('PEComa') of the uterus. A subset of HMB-45 positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumours. Am J Surg Pathol 2002; 26: 1–13.
  • Vang R, Whitaker BP, Farhood Al, et al. Immunohistochemical analysis of clear cell carcinoma of the gynaecologic tract. Int J Gynecol Pathol 2001; 20: 252–9.
  • Nolan LT, Heatley MK. The value of immunohistochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol 2001; 20: 155–9.
  • Ordi J, Romagosa C, Tavassoli FA, et al. CD10 Expression in epithelial tissues and tumours of the gynaecologic tract. A useful marker in the diagnosis of mesonephric, trophoblastic and clear cell tumours. Am J Surg Pathol 2003; 27: 178–86.
  • Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002; 40: 237–44.
  • Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumours: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002; 21: 391–400.
  • Albarracin CT, Jafri J, Montag AG, et al. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000; 31: 672–7.
  • Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than a-inhibin for ovarian sex cord-stromal neoplasms. An immunohistochemical study of 215 cases. Am J Surg Pathol 2002; 26: 1477–83.
  • Castrillon DH, Sun D, Weremowicz S, et al. Discrimination of complete hydatidiform mole from its mimics by immunohistochem-istry of the paternally imprinted gene product p57 (KIP 2). Am J Surg Pathol 2001; 25: 1225–30.
  • Singer G, Kurman RJ, McMaster MT, et al. HLA-G Immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2003; 26: 914–20.
  • Chu P, Arber DA. Paraffin-section detection of CD10 in 505 non-hematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000; 113: 374–82.
  • McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology 2003; 43: 144–50.
  • McCluggage WG, Jenkins D. p16 Immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003; 22: 231–5.
  • Masumoto N, Fujii T, Ishikawa M, et al. p16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003; 34: 778–83.
  • Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16 overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol 2003; 22: 378–85.
  • Jun S-Y, Ro JY, Kim K-R. p57 (kip2) is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathology 2003; 43: 17–25.
  • Cameron RI, Ashe P, O'Rourke DM, et al. A panel of immuno-histochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 2003; 22: 272–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.